Powered by

Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2021

Jul 21, 2021 - Business Wire
Board and Executive Moves

POXEL SA (Euronext - POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced its cash position and revenue for the second quarter and first half of 2021.

"Following our recent achievements, we are excited to leverage our proven capabilities and existing platforms to execute upon our new strategic direction...